James Zou, PhD: No financial relationships to disclose
AI agents are large language models equipped with tools that can autonomously tackle challenging tasks. This talk will explore how generative AI agents can enable drug discovery and development. For discovery, I’ll introduce the Virtual Lab—a collaborative team of AI scientist agents conducting in silico research meetings to tackle open-ended R&D projects. As an example application, the Virtual Lab designed new nanobody binders to recent Covid variants that we experimentally validated. Then I will discuss AI agents for drug development by discussing how AI agents can help with analysis of drug toxicity and clinical trial design.
